Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells

Cancer Letters

Volumn 343, Issue 2, 2014, Pages 217-223

  McPherson, Lisa A ^a   Shen, Yuqiao ^b   Ford, James M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

Colorectal cancer; DNA damage; MRE11; MSI; PARP inhibitors

Indexed keywords

5 FLUORO 8 (4 FLUOROPHENYL) 9 (1 METHYL 1H IMIDAZOL 2 YL) 8,9 DIHYDRO 2H PYRIDO[4,3,2 DE]PHTHALAZIN 3(7H) ONE; CISPLATIN; FIRTECAN; LT 625; LT 626; MRE11 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; OXALIPLATIN; PLATINUM COMPLEX; UNCLASSIFIED DRUG; VELIPARIB;

ARTICLE; CANCER CELL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; MICROSATELLITE INSTABILITY; MRE11 GENE; PRIORITY JOURNAL;

COLORECTAL CANCER; DNA DAMAGE; MRE11; MSI; PARP INHIBITORS;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CAMPTOTHECIN; CELL LINE, TUMOR; CISPLATIN; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; DRUG SYNERGISM; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INHIBITORY CONCENTRATION 50; MUTATION; PHTHALAZINES; PLATINUM; POLY(ADP-RIBOSE) POLYMERASES; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84891834093     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.10.034     Document Type: Article

References (29)

1. Burt R.W., Barthel J.S., Dunn K.B., David D.S., Drelichman E., Ford J.M., Giardiello F.M., Gruber S.B., Halverson A.L., Hamilton S.R., Ismail M.K., Jasperson K., Lazenby A.J., Lynch P.M., Martin E.W., Mayer R.J., Ness R.M., Provenzale D., Rao M.S., Shike M., Steinbach G., Terdiman J.P., Weinberg D. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J. Natl. Compr. Cancer Networks 2010, 8:8-61.
2. Hampel H., Stephens J.A., Pukkala E., Sankila R., Aaltonen L.A., Mecklin J.P., de la Chapelle A. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005, 129:415-421.
3. Lynch H.T., de la Chapelle A. Hereditary colorectal cancer. N. Engl. J. Med. 2003, 348:919-932.
4. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J. Clin. Oncol. 2003, 21:1174-1179.
5. Colas C., Coulet F., Svrcek M., Collura A., Flejou J.F., Duval A., Hamelin R. Lynch or not Lynch? Is that always a question?. Adv. Cancer Res. 2012, 113:121-166.
6. Alhopuro P., Sammalkorpi H., Niittymaki I., Bistrom M., Raitila A., Saharinen J., Nousiainen K., Lehtonen H.J., Heliovaara E., Puhakka J., Tuupanen S., Sousa S., Seruca R., Ferreira A.M., Hofstra R.M., Mecklin J.P., Jarvinen H., Ristimaki A., Orntoft T.F., Hautaniemi S., Arango D., Karhu A., Aaltonen L.A. Candidate driver genes in microsatellite-unstable colorectal cancer. Int. J. Cancer 2012, 130:1558-1566.
7. Hugo H., Cures A., Suraweera N., Drabsch Y., Purcell D., Mantamadiotis T., Phillips W., Dobrovic A., Zupi G., Gonda T.J., Iacopetta B., Ramsay R.G. Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers. Genes Chromosomes Cancer 2006, 45:1143-1154.
8. Giannini G., Ristori E., Cerignoli F., Rinaldi C., Zani M., Viel A., Ottini L., Crescenzi M., Martinotti S., Bignami M., Frati L., Screpanti I., Gulino A. Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep. 2002, 3:248-254.
9. Vilar E., Scaltriti M., Balmana J., Saura C., Guzman M., Arribas J., Baselga J., Tabernero J. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br. J. Cancer 2008, 99:1607-1612.
10. Wen Q., Scorah J., Phear G., Rodgers G., Rodgers S., Meuth M. A mutant allele of MRE11 found in mismatch repair-deficient tumor cells suppresses the cellular response to DNA replication fork stress in a dominant negative manner. Mol. Biol. Cell 2008, 19:1693-1705.
11. Vilar E., Bartnik C.M., Stenzel S.L., Raskin L., Ahn J., Moreno V., Mukherjee B., Iniesta M.D., Morgan M.A., Rennert G., Gruber S.B. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 2011, 71:2632-2642.
12. Telli M.L., Ford J.M. PARP inhibitors in breast cancer. Clin. Adv. Hematol. Oncol. 2010, 8:629-635.
13. Chou T.-C., Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol. Sci. 1983, 4:450-454.
14. Penning T.D., Zhu G.D., Gandhi V.B., Gong J., Liu X., Shi Y., Klinghofer V., Johnson E.F., Donawho C.K., Frost D.J., Bontcheva-Diaz V., Bouska J.J., Osterling D.J., Olson A.M., Marsh K.C., Luo Y., Giranda V.L. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J. Med. Chem. 2009, 52:514-523.
15. Menear K.A., Adcock C., Boulter R., Cockcroft X.L., Copsey L., Cranston A., Dillon K.J., Drzewiecki J., Garman S., Gomez S., Javaid H., Kerrigan F., Knights C., Lau A., Loh V.M., Matthews I.T., Moore S., O'Connor M.J., Smith G.C., Martin N.M. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J. Med. Chem. 2008, 51:6581-6591.
16. Audeh M.W., Carmichael J., Penson R.T., Friedlander M., Powell B., Bell-McGuinn K.M., Scott C., Weitzel J.N., Oaknin A., Loman N., Lu K., Schmutzler R.K., Matulonis U., Wickens M., Tutt A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
17. Hastak K., Alli E., Ford J.M. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 2010, 70:7970-7980.
18. Lord C.J., McDonald S., Swift S., Turner N.C., Ashworth A. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 2008, 7:2010-2019.
19. Vaisman A., Varchenko M., Umar A., Kunkel T.A., Risinger J.I., Barrett J.C., Hamilton T.C., Chaney S.G. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res. 1998, 58:3579-3585.
20. Fink D., Nebel S., Aebi S., Zheng H., Cenni B., Nehme A., Christen R.D., Howell S.B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 1996, 56:4881-4886.
21. Magrini R., Bhonde M.R., Hanski M.L., Notter M., Scherubl H., Boland C.R., Zeitz M., Hanski C. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int. J. Cancer 2002, 101:23-31.
22. Jacob S., Aguado M., Fallik D., Praz F. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res. 2001, 61:6555-6562.
23. LoRusso P., Ji J.J., Li J., Heilbrun L.K., Shapiro G., Sausville E.A., Boerner S.A., Smith D.W., Pilat M.J., Zhang J., Chen A.P., Nechiporchik N., Parchment R.E. Phase I study of the safety, pharmacokinetics (PK), pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; IR) in patients (pts) with advanced solid tumors. J. Clin. Oncol. 2011, 29. suppl; abstr 3000.
24. Papadopoulos N., Nicolaides N.C., Wei Y.F., Ruben S.M., Carter K.C., Rosen C.A., Haseltine W.A., Fleischmann R.D., Fraser C.M., Adams M.D., et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994, 263:1625-1629.
25. Koi M., Umar A., Chauhan D.P., Cherian S.P., Carethers J.M., Kunkel T.A., Boland C.R. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 1994, 54:4308-4312.
26. Veigl M.L., Kasturi L., Olechnowicz J., Ma A.H., Lutterbaugh J.D., Periyasamy S., Li G.M., Drummond J., Modrich P.L., Sedwick W.D., Markowitz S.D. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc. Natl. Acad. Sci. USA 1998, 95:8698-8702.
27. Liu B., Nicolaides N.C., Markowitz S., Willson J.K., Parsons R.E., Jen J., Papadopolous N., Peltomaki P., de la Chapelle A., Hamilton S.R., et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat. Genet. 1995, 9:48-55.
28. Umar A., Boyer J.C., Thomas D.C., Nguyen D.C., Risinger J.I., Boyd J., Ionov Y., Perucho M., Kunkel T.A. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J. Biol. Chem. 1994, 269:14367-14370.
29. Papadopoulos N., Nicolaides N.C., Liu B., Parsons R., Lengauer C., Palombo F., D'Arrigo A., Markowitz S., Willson J.K., Kinzler K.W., et al. Mutations of GTBP in genetically unstable cells. Science 1995, 268:1915-1917.